Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
BeOne MedicinesFRA:49BA +4.26%79 Debt-to-Equity is 0.22 as of Jun. 2026, which is 22% above its 10-year median of 0.18. GuruFocus rates FRA:49BA with a GF Score™ of 79/100 and a GF Value™ of €316.42 (Fairly Valued). The stock has 5 warning signs investors should review. Among 971 Biotechnology companies, BeOne Medicines ranks worse than 58.81% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for BeOne Medicines's Debt-to-Equity or its related term are showing as below:
FRA:49BA'
s Debt-to-Equity Range Over the Past 10 Years
Min: 0.05 Med: 0.18 Max: 0.6
Current: 0.22
During the past 13 years, the highest Debt-to-Equity Ratio of BeOne Medicines was 0.60. The lowest was 0.05. And the median was 0.18.
FRA:49BA's Debt-to-Equity is ranked worse than 58.81% of 971
companies
in the Biotechnology industry
Industry Median: 0.16
vs FRA:49BA: 0.22
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
BeOne Medicines Debt-to-Equity Related Terms
BeOne Medicines Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for BeOne Medicines's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:49BA vs ALNY, RVMD, RPRX: Debt-to-Equity Comparison
For the Biotechnology subindustry, BeOne Medicines's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BeOne Medicines Debt-to-Equity vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, BeOne Medicines's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where BeOne Medicines's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BeOne Medicines (FRA:49BA) has a Debt-to-Equity of 0.22 as of Jun. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on BeOne Medicines and its competitors. This is 22% above median its historical median of 0.18. Over the past decade, BeOne Medicines' Debt-to-Equity has ranged from 0.05 to 0.60. According to the industry distribution chart, BeOne Medicines ranks #571 out of 971 companies in the Biotechnology industry, placing it in the top 58.8%.
Is BeOne Medicines' Debt-to-Equity too high?
BeOne Medicines' current Debt-to-Equity of 0.22 is 22% above median its 10-year median of 0.18. Over the past 10 years, this metric has ranged from a low of 0.05 to a high of 0.60. The Biotechnology industry median Debt-to-Equity is 0.16. BeOne Medicines' value of 0.22 is 37.5% above this industry median. Based on the distribution chart, BeOne Medicines ranks #571 out of 971 companies in the Biotechnology industry, which is below the industry midpoint. Overall, BeOne Medicines has a GF Score™ of 79/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does BeOne Medicines' Debt-to-Equity compare to ALNY and RVMD?
According to the Biotechnology industry distribution chart, BeOne Medicines ranks #571 out of 971 companies for Debt-to-Equity. This places BeOne Medicines in the lower half of its industry. The industry median Debt-to-Equity is 0.16. BeOne Medicines' value of 0.22 is 37.5% above this benchmark. Historically, BeOne Medicines' own Debt-to-Equity has ranged from 0.05 to 0.60 over the past decade. While the company's 10-year median is 0.18 vs. the industry median of 0.16, BeOne Medicines has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Biotechnology company?
The median Debt-to-Equity among Biotechnology companies is 0.16, based on 971 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. BeOne Medicines's current Debt-to-Equity of 0.22 is 37.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on BeOne Medicines and its competitors. For the Biotechnology industry, the median Debt-to-Equity is 0.16 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BeOne Medicines's current Debt-to-Equity is 0.22, which is 22% above median its own 10-year median of 0.18. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BeOne Medicines stock overvalued right now?
Based on GuruFocus' analysis, BeOne Medicines (FRA:49BA) is currently considered Fairly Valued. The stock's GF Value™ is €316.42, compared to a current price of €294.00 — trading 7.1% below its estimated fair value. The current Debt-to-Equity is 0.22, which is 22% above median its 10-year median of 0.18 and 37.5% above the Biotechnology industry median of 0.16. BeOne Medicines' overall GF Score™ is 79/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For BeOne Medicines (FRA:49BA), the current Debt-to-Equity is 0.22 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is BeOne Medicines (FRA:49BA) Overvalued in 2026?
Based on GuruFocus' analysis, BeOne Medicines stock appears to be undervalued.
The current stock price of €294.00 is trading 7.1% below its estimated GF Value™ of €316.42.
GuruFocus considers BeOne Medicines to be Fairly Valued.
Key valuation signals for FRA:49BA:
Debt-to-Equity: 0.22 (22% above median its 10-year median of 0.18)
GF Value™: €316.42 vs. price of €294.00 (7.1% below fair value)
Industry Position: 37.5% above the Biotechnology median (#571 of 971)
No single metric tells the full story. See the FRA:49BA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Formerly known as BeiGene and founded in 2010 in Beijing, BeOne is a commercial-stage biotech firm that produces oncology therapeutics. The company's main product is Brukinsa, which is a small-molecule drug that treats multiple forms of Non-Hodgkin lymphoma and leukemia. The company conducts drug discovery, runs global clinical trials, and manufactures drugs independently. As of 2025, Brukinsa made up for 74% of total revenue, while it has two other approved commercialized drugs in its portfolio, Beqalzi and Tevimbra. While Brukinsa has a global leadership, the other two drugs generate revenue mostly from China. Based on Brukinsa, BeOne competes with AbbVie and AstraZeneca mainly. The company also has more than 50 drugs in clinical trials in its active pipeline, focused on other cancers.
79GF Score
Get the complete analysis for FRA:49BA
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:49BA has been successfully added to your 
